| Name | Title | Contact Details |
|---|
Hyperion Clinical Research, LLC is a Charleston, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Established in January, 2000, following the consolidation of St. Elizabeth Hospital and Elizabeth General Medical Center, Trinitas Regional Medical Center is a full-service healthcare facility serving those who live and work in Eastern and Central Union County. Operating on two major campuses, Trinitas Regional Medical Center has 554 beds, including a 120-bed long-term care center. Trinitas Regional Medical Center is proud to offer state-of-the-art medicine backed by compassion and competence. Our friendly, professional staff and skilled physicians are the foundation of the care we provide. Together, our medical team offers the community the most advanced technological care in every area of medicine and surgery. Utilizing a full spectrum of sophisticated inpatient, outpatient and long-term care services, Trinitas Regional Medical Center is proud to have forged a lifelong partnership with families, physicians and communities to provide the best care in a supportive and caring environment. We treat over 17,000 inpatients annually, 70,000 emergency patients, and several hundred thousand outpatients. Trinitas Regional Medical Center is pleased to offer a number of Centers of Excellence and specialized major services, including Behavioral Health,Bloodless Medicine, Cancer Care, Cardiology, Diabetes Management,Maternal and Child Health, Renal Services, School of Nursing, Senior Services, Sleep Disorders, Women`s Services, Wound Healing and more. A Catholic teaching hospital, Trinitas Regional Medical Center is sponsored by the Sisters of Charity of Saint Elizabeth in partnership with Elizabethtown Healthcare Foundation.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
Gympass partners with companies to offer employees unlimited access to the world`s largest fitness network at 70% off market prices. Spanning 14 countries, we pair our unmatched variety and flexible membership options with consistent, tailored programming that inspires your workforce to enroll, stay motivated, and unlock their full potential. With one membership you access thousands of gyms and studios plus live-stream classes and wellness apps. Our unique approach is designed to propel employee engagement, improve individual performance, and enable business success by revolutionizing corporate wellness.
Meta Nutrition - The platform that knows what to eat!